Erlich TH, Fisher DE.
2018.
Pathways in melanoma development.. G Ital Dermatol Venereol. 153(1):68-76.
Du S, Zhou L, Alexander GS, Park K, Yang L, Wang N, Zaorsky NG, Ma X, Wang Y, Dicker AP et al..
2018.
PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes.. J Thorac Oncol. 13(4):510-520.
El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H et al..
2018.
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.. Cancer Chemother Pharmacol. 81(5):957-963.
Belkacemi L, Atkins JL, Yang LU, Gadgil P, Sater AK, Chow DS, Bose RN, Zhang SXiaoliu.
2018.
Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly an Up-regulation of PEDF in Breast Cancer.. Anticancer Res. 38(2):623-646.
Lockney NA, Wang DG, Pei X, Goldman DA, Zhang Z, Lin A, Chan TA, Yamada Y, Beal K, T Yang J.
2018.
Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.. Int J Radiat Oncol Biol Phys. 101(4):833-844.
Greenberg E, Tung ES, Gauvin C, Osiecki L, Yang KG, Curley E, Essa A, Illmann C, Sandor P, Dion Y et al..
2018.
Prevalence and predictors of hair pulling disorder and excoriation disorder in Tourette syndrome.. Eur Child Adolesc Psychiatry. 27(5):569-579.
Lee J-M, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee M-J et al..
2018.
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.. Lancet Oncol. 19(2):207-215.
Malekmohammadi M, AuYong N, Price CM, Tsolaki E, Hudson AE, Pouratian N.
2018.
Propofol-induced Changes in α-β Sensorimotor Cortical Connectivity.. Anesthesiology. 128(2):305-316.
Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P et al..
2018.
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes.. Int J Radiat Oncol Biol Phys. 100(2):374-382.